Logo image of SRPT

SAREPTA THERAPEUTICS INC (SRPT) Stock Fundamental Analysis

NASDAQ:SRPT - US8036071004 - Common Stock

20.22 USD
+0.16 (+0.8%)
Last: 8/22/2025, 8:00:00 PM
20.21 USD
-0.01 (-0.05%)
After Hours: 8/22/2025, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, SRPT scores 3 out of 10 in our fundamental rating. SRPT was compared to 547 industry peers in the Biotechnology industry. SRPT may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, SRPT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year SRPT has reported negative net income.
SRPT had a negative operating cash flow in the past year.
In the past 5 years SRPT reported 4 times negative net income.
In the past 5 years SRPT reported 4 times negative operating cash flow.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

The Return On Assets of SRPT (-1.57%) is better than 88.71% of its industry peers.
SRPT has a better Return On Equity (-4.27%) than 89.62% of its industry peers.
Industry RankSector Rank
ROA -1.57%
ROE -4.27%
ROIC N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

With an excellent Gross Margin value of 79.28%, SRPT belongs to the best of the industry, outperforming 84.52% of the companies in the same industry.
SRPT's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SRPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SRPT has more shares outstanding
Compared to 5 years ago, SRPT has more shares outstanding
SRPT has a better debt/assets ratio than last year.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 0.05, we must say that SRPT is in the distress zone and has some risk of bankruptcy.
SRPT has a better Altman-Z score (0.05) than 61.57% of its industry peers.
A Debt/Equity ratio of 0.84 indicates that SRPT is somewhat dependend on debt financing.
SRPT has a worse Debt to Equity ratio (0.84) than 75.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Altman-Z 0.05
ROIC/WACCN/A
WACC8.41%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 2.89 indicates that SRPT has no problem at all paying its short term obligations.
SRPT's Current ratio of 2.89 is on the low side compared to the rest of the industry. SRPT is outperformed by 64.85% of its industry peers.
SRPT has a Quick Ratio of 1.81. This is a normal value and indicates that SRPT is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.81, SRPT is doing worse than 76.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.89
Quick Ratio 1.81
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SRPT have decreased strongly by -293.33% in the last year.
Looking at the last year, SRPT shows a very strong growth in Revenue. The Revenue has grown by 64.89%.
The Revenue has been growing by 37.94% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-293.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2600%
Revenue 1Y (TTM)64.89%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%68.38%

3.2 Future

Based on estimates for the next years, SRPT will show a small growth in Earnings Per Share. The EPS will grow by 0.81% on average per year.
The Revenue is expected to decrease by -6.31% on average over the next years.
EPS Next Y-309.16%
EPS Next 2Y-7.31%
EPS Next 3Y-19.39%
EPS Next 5Y0.81%
Revenue Next Year9.01%
Revenue Next 2Y-8.54%
Revenue Next 3Y-6.19%
Revenue Next 5Y-6.31%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 -4 -6 -8

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

SRPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 10.32 indicates a reasonable valuation of SRPT.
97.45% of the companies in the same industry are more expensive than SRPT, based on the Price/Forward Earnings ratio.
SRPT's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.81.
Industry RankSector Rank
PE N/A
Fwd PE 10.32
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SRPT indicates a rather cheap valuation: SRPT is cheaper than 91.26% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 50.45
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

A cheap valuation may be justified as SRPT's earnings are expected to decrease with -19.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.31%
EPS Next 3Y-19.39%

More info and screens

0

5. Dividend

5.1 Amount

SRPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (8/22/2025, 8:00:00 PM)

After market: 20.21 -0.01 (-0.05%)

20.22

+0.16 (+0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners96.69%
Inst Owner Change-3.06%
Ins Owners4.4%
Ins Owner Change2.95%
Market Cap1.98B
Analysts67.22
Price Target33.58 (66.07%)
Short Float %22.3%
Short Ratio1.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-114.71%
Min EPS beat(2)-376.26%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)24.21%
Min EPS beat(4)-376.26%
Max EPS beat(4)348.76%
EPS beat(8)6
Avg EPS beat(8)617.4%
EPS beat(12)8
Avg EPS beat(12)384.79%
EPS beat(16)10
Avg EPS beat(16)285.72%
Revenue beat(2)2
Avg Revenue beat(2)9.95%
Min Revenue beat(2)6.86%
Max Revenue beat(2)13.04%
Revenue beat(4)4
Avg Revenue beat(4)8.67%
Min Revenue beat(4)2.86%
Max Revenue beat(4)13.04%
Revenue beat(8)7
Avg Revenue beat(8)5.95%
Revenue beat(12)9
Avg Revenue beat(12)3.94%
Revenue beat(16)12
Avg Revenue beat(16)3.6%
PT rev (1m)-32.47%
PT rev (3m)-77.76%
EPS NQ rev (1m)-42.98%
EPS NQ rev (3m)-118.37%
EPS NY rev (1m)-14.36%
EPS NY rev (3m)-145.76%
Revenue NQ rev (1m)-2%
Revenue NQ rev (3m)-57.05%
Revenue NY rev (1m)-8.77%
Revenue NY rev (3m)-21.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.32
P/S 0.8
P/FCF N/A
P/OCF N/A
P/B 1.46
P/tB 1.49
EV/EBITDA 50.45
EPS(TTM)-0.87
EYN/A
EPS(NY)1.96
Fwd EY9.69%
FCF(TTM)-4.65
FCFYN/A
OCF(TTM)-3.08
OCFYN/A
SpS25.4
BVpS13.89
TBVpS13.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.57%
ROE -4.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.28%
FCFM N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score2
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Debt/EBITDA 28.38
Cap/Depr 372.98%
Cap/Sales 6.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.89
Quick Ratio 1.81
Altman-Z 0.05
F-Score2
WACC8.41%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-293.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2600%
EPS Next Y-309.16%
EPS Next 2Y-7.31%
EPS Next 3Y-19.39%
EPS Next 5Y0.81%
Revenue 1Y (TTM)64.89%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%68.38%
Revenue Next Year9.01%
Revenue Next 2Y-8.54%
Revenue Next 3Y-6.19%
Revenue Next 5Y-6.31%
EBIT growth 1Y-102.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-308.31%
EBIT Next 3Y-28%
EBIT Next 5Y-24.41%
FCF growth 1Y15.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.48%
OCF growth 3YN/A
OCF growth 5YN/A